Cardiovascular Diseases

The Klinisches Forschungszentrum Dr. Hagemann conducts research aimed at reducing the burden of cardiovascular disease by testing new therapies and preventive strategies. Studies target conditions such as atherosclerosis, heart rhythm disorders, and blood pressure control, with the goal of improving long‑term outcomes for patients at high risk.

  • Atherosclerotic cardiovascular disease
  • Atrial fibrillation
  • Heart failure
  • Hypertension
  • Hypercholesterolemia

This work supports the site’s role as an educational institution while collaborating with commercial partners to bring innovative cardiovascular solutions to the community.

Nutritional and Metabolic Diseases

Researchers at the Hausarztzentrum am Germaniaplatz focus on metabolic health, evaluating interventions that address type 2 diabetes and obesity. The trials aim to improve glycaemic control, reduce body weight, and lower cardiovascular risk associated with metabolic disorders.

  • Type 2 diabetes
  • Obesity
  • Hyperlipidemia
  • Metabolic syndrome
  • Chronic kidney disease

By integrating clinical care with research, the site advances therapeutic options for patients with metabolic conditions.

Respiratory Tract Diseases

The centre investigates acute respiratory infections, including acute bronchitis, to determine the effectiveness of novel and herbal treatments. Objectives include reducing symptom severity and shortening illness duration, thereby enhancing patient recovery.

  • Acute bronchitis
  • Upper respiratory infection
  • Cough and mucus production
  • Symptom severity scores
  • Treatment safety profiles

This research contributes to better management of common respiratory ailments in the local population.

Virus Diseases

Studies at the site evaluate vaccine immunogenicity and protection against influenza, especially in adults over 50 years of age. The trials assess immune response, safety, and the ability of new formulations to prevent viral illness.

  • Influenza vaccine efficacy
  • Immunogenicity in older adults
  • Safety of high‑dose formulations
  • Cellular immune response
  • Prevention of virus‑related complications

These efforts align with public health goals to reduce seasonal flu impact and support the site’s educational mission.